Form 4: Nu Skin CPO Buys 5,500 Shares in Planned Transaction

Nu Skin Enterprises' Chief Product Officer, Steven Hatchett, reported the acquisition of 5,500 shares of Class A Common Stock at $9.61 per share, effective November 11, 2025, under a Rule 10b5-1 plan.

Summary

• Steven Hatchett, Chief Product Officer of Nu Skin Enterprises, Inc. (NUS), acquired 5,500 shares of Class A Common Stock.
• The transaction price for the shares was $9.61 per share.
• The reported transaction date for this acquisition is November 11, 2025.
• This purchase was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Following this transaction, Hatchett directly beneficially owns 167,565 shares of Class A Common Stock.
• A Limited Power of Attorney, dated May 22, 2025, grants several individuals the authority to prepare and file SEC reports on Hatchett's behalf.

Sentiment

Score: 7

Explanation: The insider purchase by a key executive, even if pre-planned, generally conveys a positive sentiment regarding the company's prospects. The future transaction date under a 10b5-1 plan suggests a deliberate, long-term investment strategy rather than opportunistic trading.

Positives

• Insider buying by a Chief Product Officer, Steven Hatchett, signals confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-planned, systematic investment strategy rather than opportunistic trading.

Risks

• The Limited Power of Attorney explicitly states that neither the Company nor any attorney-in-fact assumes liability for the undersigned's responsibility to comply with Exchange Act or Securities Act requirements, or for profit disgorgement under Section 16(b) of the Exchange Act.
• The Power of Attorney does not relieve the undersigned from responsibility for compliance with obligations under the Exchange Act or Securities Act, including Section 16 reporting requirements.

Future Outlook

The reported transaction, executed under a Rule 10b5-1 plan, indicates a pre-scheduled future acquisition of company stock by a key executive, reflecting a long-term investment perspective.

Industry Context

Insider purchases, particularly by high-ranking officers like a Chief Product Officer, are often viewed by the market as a signal of management's confidence in the company's future performance and strategic direction, potentially indicating a belief that the stock is undervalued or poised for growth. The use of a 10b5-1 plan suggests a structured, pre-planned approach to personal investment, aiming to avoid accusations of trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal of management confidence, potentially influencing investment decisions.
• Employees: Could interpret the executive's investment as a sign of stability and belief in the company's future.

Key Dates

Recommendation

While insider buying is generally a positive signal, this transaction is a relatively small purchase for a high-ranking executive (approximately $52,855) and is pre-planned under a 10b5-1 plan for a future date. This suggests a systematic investment rather than an immediate, opportunistic buy based on new, undisclosed positive information. Therefore, it provides a modest positive signal but is not strong enough to warrant an immediate 'buy' recommendation without further fundamental analysis of the company's overall financial health and market position. A 'hold' recommendation is appropriate, acknowledging the positive insider sentiment while awaiting more comprehensive data.

Keywords

Nu Skin Enterprises, NUS, Steven Hatchett, Insider Trading, Form 4, Stock Purchase, Chief Product Officer, 10b5-1 Plan, Equity Acquisition